Genzyme has detected a virus that impairs cell growth in one of six bioreactors at Allston Landing manufacturing facility. So, the company has decided to temporarily stop bulk production at the plant to sanitize the facility.
The company expects the plant to be fully operational by the end of July.
The virus strain, Vesivirus 2117 found, is known to interfere with the growth of CHO cells used to produce biologic drugs, and was likely introduced through a nutrient used in the manufacturing process.
Genzyme is adding steps to increase the robustness of raw materials screening and viral removal processes.
Henri Termeer, Chairman and CEO of Genzyme, said: “We are confident in the quality of the products produced in Allston and in our ability to resolve the issue affecting the plant. The impact will be temporary.”